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Abstract
Introduction: Chest X-ray (CXR) has been used since long as an aid in the diagnosis of pulmonary tuberculosis (PTB) and also 
to determine the extent of the disease. The present study was conducted to evaluate the correlation of disease extent on CXR 
based on the Timika CXR score with clinical and microbiological parameters at baseline, in sputum positive cases of pulmonary 
tuberculosis.
Material and methods: The study was conducted at a tertiary referral centre for chest diseases in Bangalore, Karnataka from 
January 2017 to January 2018. This is a prospective study of new sputum smear positive pulmonary tuberculosis cases diagno-
sed in the Department of Pulmonary Medicine. At baseline, patients’ symptoms and signs on chest auscultation were recorded. 
The clinical scoring was done by the Karnofsky performance score (KPS) and TB score I (Bandim TB score) and II. Baseline CXR 
postero-anterior (PA) view of each patient was assessed independently by two chest physicians and evaluated by the Timika 
CXR scoring method. Routine blood investigations and sputum smear for acid fast bacilli were done. The correlation between the 
CXR score and other disease severity parameters was analysed.
Results: Clinical scores such as the KPS and TB score I and II, did not correlate with the presence of cavitary disease on CXR 
(p > 0.05). 48.6% of patients with cavitary disease had higher baseline AFB density in sputum (i.e. sputum smear microscopy 
grade 3+) as compared to 40% of patients with non cavitary disease, which was not statistically significant. CXR score > 71 was 
significantly associated with longer duration of symptoms, higher clinical scores (KPS and TB score I, II) and lower Body Mass Index 
(BMI) at diagnosis of PTB (p < 0.05). 65.2% of the patients with CXR score > 71 had significantly higher baseline AFB density 
as compared to only 32.4% with CXR score ≤ 71 (p < 0.04). CXR score > 71 also had significant association with higher ESR. 
Conclusion: Cavitary disease on CXR is associated with a higher mycobacterial load at baseline. The Timika CXR score is a sim-
ple, standard scoring system which can be used by a chest physician in a clinical setting. The CXR score significantly correlates 
with a broad range of clinical and microbiological measures of disease severity in PTB patients. Thus, it has a role in risk stratifi-
cation, especially in patients not producing sputum or sputum negative PTB at diagnosis. 
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Introduction
Tuberculosis has a high impact on global 
health as the ninth leading cause of death world-
wide. Among the infectious diseases it is the 
leading cause of death as per the Global Tuber-
culosis Report 2017 [1]. Due to the tremendous 
improvement in the diagnostic modalities like 
molecular assays, the detection of pulmonary 
tuberculosis (PTB) in the recent years has been 
easier [2]. In India, the treatment of tuberculosis 
is well established and standardised under the na-
tional programme [2]. However, many factors in-
fluence the treatment response and outcome. The 
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disease extent and severity at diagnosis help to 
predict the treatment response and outcome [3]. 
Studies have shown that persistent sputum po-
sitivity at the end of 2 months of treatment is 
one of the predictors of unfavourable treatment 
outcome [3–7]. Higher smear grades on sputum 
smear microscopy, extensive lung involvement 
and the presence of cavities on chest X-ray (CXR) 
at diagnosis are among the factors associated with 
persistent sputum positivity [3, 8–10].
CXR has been used since long as an aid in 
the diagnosis of tuberculosis and also to determi-
ne the extent of the disease. Major limitation in 
determing the disease extent on CXR is the ab-
sence of a validated standard scoring system [11]. 
Ralph et al. [12] recently derived a simple CXR 
disease severity score from adults with smear-po-
sitive PTB in Indonesia. They found an associa-
tion between month 2 sputum smear status and 
the participant’s baseline ‘Timika X-ray score’ 
(total percentage of affected lung on CXR + 40 if 
cavitation is present). They also concluded that 
availability of a valid and accurate CXR score may 
help to stratify the patients into high risk groups 
in terms of treatment outcome [12].
The present study was conducted to evalu-
ate the correlation of the disease extent on CXR 
based on the Timika CXR score with clinical and 
microbiological parameters at baseline, in sputum 
positive cases of pulmonary tuberculosis.
Material and methods
The study was conducted at a tertiary referral 
centre for chest diseases in Bangalore, Karnataka 
from January 2017 to January 2018. This is a pro-
spective study of new sputum smear positive 
pulmonary tuberculosis cases diagnosed in the 
Department of Pulmonary Medicine. The study 
protocol was approved independently by the 
institutional ethical committee and the ethical 
committee of IISc.
Inclusion criteria:
 — New sputum smear positive pulmonary tuber-
culosis patients aged > 18 years; male/female; 
HIV negative; without any comorbidities.
Exclusion criteria:
 — Previously treated tuberculosis cases ; HIV- 
positive cases; any other viral illness; severe 
comorbidities; pregnant women; those not 
willing to give written consent for the parti-
cipation.
 — At baseline, patients’ symptoms and signs on 
chest auscultation were recorded. The clinical 
assessment was done by the Karnofsky perfor-
mance score (KPS) and TB score I (Bandim 
TB score) and II (Table 1).
 —  Routine blood investigations were done 
specifically haemoglobin percentage, ESR 
and serum albumin.
 — A standard 6-foot posteroanterior (PA) chest 
radiograph was obtained for all patients. Ca-
vitary disease was defined as the presence of 
a gas-containing lucent space at least 1cm in 
diameter within the lung parenchyma surro-
unded by an infiltrate or fibrotic wall greater 
than 1 mm thick. Each X-ray film was exami-
ned independently by two experienced chest 
physicians blinded to each other’s readings. 
The extent of lung involvement was assessed 
using the radiological score described by 
Ralph et al. [12], which takes into account 
the proportion of the lung affected and the 
presence of cavitation. 
 — The Timika score [12] is calculated as descri-
bed in Table 2.
 — Sputum smear grading was assessed using Zie-
hl-Neelsen staining method. The results were 
reported as per the national guidelines [13, 14]. 
 — All the cases were treated with the stan-
dard DOTS (Directly Observed Treatment 
Strategy) Category I regimen under RNTCP 
(Revised National Tuberculosis Control Pro-
gramme) [2].
Table 1.  Calculation of TB score I and II









Pulse > 90 beats/min 1
Positive finding at lung auscul-
tation
1
Temperature > 370C 1
BMI < 18 1 1
BMI < 16 1 1
MUAC < 220 mm 1 1
MUAC < 200 mm 1 1
Total number of points possible 13 8
BMI —  body mass index, MUAC — mid upper arm circumference
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Table 2. Calculation of Timika score
Full-size postero-anterior chest X-ray (CXR-PA view) with proper position and penetration were used for scoring. The CXR was divided into 
six zones of roughly similar size with two horizontal lines 
For each zone, the percentage area that showed active disease (consolidation, nodules) involvement was estimated depending on the visu-
al estimation of the extent of opacification (5 or 10–100% in 10% increments)
The percentage of all six zones were added and divided by 600 to get the total percentage of lung affected
A constant value of 40 was added to the above value if at least one cavity was identified to obtain the final score
CRX score = proportion of total lung affected (%) + 40 if cavitations present
 — The statistical software, namely SPSS 18.0 
and R environment ver.3.2.2 were used for 
the analysis of the data and Microsoft Word 
and Excel have been used to generate graphs, 
tables etc. The results of continuous me-
asurements are presented as Mean ± SD 
(Min-Max) and the results of categorical 
measurements are illustrated in numbers (%).
Student t test (two-tailed, independent) has 
been used to find the significance of the study 
parameters on a continuous scale between two 
groups (intergroup analysis) on metric parame-
ters. Leven’s test for homogeneity of variance 
has been performed to assess the homogeneity of 
variance. Chi-square/ Fisher exact test has been 
used to find the significance of the study parame-
ters on a categorical scale between two or more 
groups, non-parametric setting for qualitative 
data analysis. Fisher exact test was used when 
cell samples were very small. 
Results
A total of 60 newly detected sputum positive 
pulmonary tuberculosis (PTB) patients were en-
rolled in the study. The median age of the study 
population was 28 years ± SD. There were 40 
(66.7%) males and 20 (33.3%) females. Thirty 
five (58.3%) patients had cavitary disease and 
25 (41.7%) had non cavitary disease on CXR. On 
applying the Timika CXR score, the median score 
of the study population was 59.5. At a cut-off level 
of CXR score of 71, 23 (38.3%) had score more or 
equal to 71 and 37 (61.7%) had scores less than 71.
The relationship between the radiological 
findings (cavitary versus non cavitary; CXR score 
≥ 71 versus CXR score < 71) at the diagnosis of 
PTB and baseline clinical and bacteriological pa-
rameters were analysed. Tables 3 and 4 summarise 
the demographic and clinical characteristics of 
the study population.
Clinical scores such as the KPS and TB 
score I  (Bandim TB score), II did not correlate 
with the presence of cavitary disease on CXR 
(p > 0.05). No significant associations were iden-
tified between cavitary disease and the duration 
of symptoms, body mass index (BMI), blood ESR, 
haemoglobin and serum albumin level (p > 0.05). 
48.6% of patients with cavitary disease had hi-
gher baseline AFB density in sputum (i.e. sputum 
smear microscopy grade 3+) as compared to 40% 
of patients with non cavitary disease, which was 
not statistically significant.
CXR score > 71 was significantly associated 
with longer duration of symptoms, higher clinical 
scores (KPS and TB score I, II) and lower BMI at 
diagnosis of PTB (p < 0.05). 65.2% of the patients 
with CXR score ≥ 71 had significantly higher 
baseline AFB density as compared to only 32.4% 
with CXR score < 71 (p < 0.04). CXR score ≥ 71 
also had a significant association with higher ESR. 
However, no significant relationships were iden-
tified between high CXR score and haemoglobin 
or serum albumin levels.
Discussion
Sputum smear microscopy and culture are 
the standard modalities for monitoring the tre-
atment response in pulmonary tuberculosis. 
A systematic review and meta-analysis done by 
Morne et al. [15] on sputum monitoring during the 
treatment of PTB for predicting the outcome conc-
luded that both sputum smear microscopy and 
culture have low sensitivity and modest specifi-
city for predicting failure and relapse. However, 
until better predictive markers are available, they 
will remain the preferred tools for monitoring 
treatment response and predicting the outcome. 
The disease severity at diagnosis determines the 
treatment result. Many surrogate markers are 
available for estimating the severity of the dise-
ase, such as high bacillary load on initial sputum 
examination, the extent of pulmonary disease and 
presence of cavitary disease on CXR at diagnosis 
[3, 8, 16, 17]. Cavitary lesions on CXR among 
PTB patients are reported to occur in 40–50% 
[8, 18, 19]. In our study population, 58.3% had 
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Table 3. Comparison of clinical variables according to cavitary or non-cavitary disease on CXR
Variables Cavitary
n = 35 (58.3%)
Non cavitary
n = 25 (41.7%)
p-value
Mean age (yrs) ± SD (median age, yrs) 32.11 ± 14.20 (28) 34.24 ± 11.78 (35) > 0.05
Gender
      Male 21 (60%) 19 (76%) > 0.05
      Female 14 (40%) 16 (64%)
Mean duration of symptoms (days) ± SD 65.86 ± 45.72 54.00 ± 38.49 > 0.05
Mean BMI (kg/m2) ± SD 17.50 ± 3.05 17.74±2.71 > 0.05
Mean KPS ± SD 74.86 ± 11.47 79.20±8.12 > 0.05
Mean TB score I ± SD 6.40 ± 2.44 5.40 ± 2.16 > 0.05
Mean TB score II ± SD 4.03 ± 1.98 3.32 ± 1.91 > 0.05
Mean Timika CXR score ± SD 80.86 ± 18.33 38.24 ± 18.91 < 0.05
Sputum AFB smear grade n (%)
      1+ 12 (34.3%) 11 (45.8%) > 0.05
      2+ 6 (17.1%) 4 (16.7%)
      3+ 17 (48.6%) 10 (40%)
Mean ESR ± SD 65.91 ± 36.13 61.74 ± 32.86 > 0.05
Mean haemoglobin (g/dl) ± SD 11.37 ± 2.05 11.91 ± 1.62 > 0.05
Mean serum albumin ± SD 3.04 ± 0.83 3.05 ± 0.78 > 0.05
Table 4. Comparison of clinical variables according to Timika score cut-off value of 71 points 
Variables Timika score ≥ 71
n = 23 (38.3%)
Timika score < 71
n = 37 (61.7%)
p-value








      Male 14 (60.9%) 26 (70.3%) > 0.05
      Female 9 (39.1%) 11 (29.7%)
Mean duration of symptoms (days) ± SD 83.04 ± 48.38 47.16 ± 32.88 < 0.05
Mean BMI (kg/m2) ± SD 16.42 ± 2.86 18.34 ± 2.69 < 0.05
Mean KPS ± SD 70.00 ± 10.87 80.81 ± 7.59 < 0.05
Mean TB score I ± SD 7.04 ± 2.65 5.32 ± 1.92 < 0.05
Mean TB score II ± SD 4.61 ± 2.04 3.19 ± 1.73 < 0.05
Cavitary 21 (91.3%) 16 (42.2%)
Sputum AFB smear grade n (%)
      1+ 5 (21.7%) 18 (48.6%) < 0.05
      2+ 3 (13.1%) 7 (18.9%)
      3+ 15 (65.2%) 12 (32.4%)
Mean ESR ± SD 77.14 ± 37.84 56.15 ± 30.19 < 0.05
Mean haemoglobin (g/dl) ± SD 11.02 ± 2.21 11.95 ± 1.59 > 0.05
Mean serum albumin ± SD 2.83 ± 0.73 3.25 ± 0.81 > 0.05
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cavitation on CXR. Patients with cavitary disease 
are shown to have a significantly higher mycobac-
terial load on sputum smear and culture [12, 20]. 
Palaci et al. [21] in their study found that about 
85% of cavitary patients had 3+ sputum smear 
grade whereas only 38% of non cavitary patients 
had 3+ smears. In our study, we could also see 
that 48.6% of patients with cavitary disease had 
3+ sputum smear grade as compared to 40% in 
patients with non cavitary disease though not 
statistically significant (p > 0.05).
KPS is a  frequently used clinical tool for 
indicating disease severity, treatment response 
and also to predict mortality [22–24]. Similarly, 
Bandim TB score and TB score II when higher at 
baseline showed increased mortality risk during 
treatment [25, 26]. Wejse et al. [27] in their study 
found that a higher TB score of > 8 at baseline 
increased the mortality to 21% vs. 11% for TB 
score < 8. Hence KPS, Bandim TB score and TB 
score II are all good clinical parameters of the 
disease severity and predictors of poor treatment 
outcome. In our study, these clinical parameters 
did not correlate with the presence or absence of 
cavitary disease on CXR.  
Low BMI and lack of weight gain during tre-
atment are found to be independent predictors of 
poor treatment outcome. Khan et al. [28] in their 
treatment trial showed that the 2 year relapse 
rate were 4.2%, 11.9% and 20.3% among those 
not underweight, those underweight but gaining 
> 5% weight at 2 months of treatment and those 
underweight and not gaining weight respectively. 
Palaci et al. [21] found that patients with cavitary 
disease had significantly lower BMI as compared 
to the patients with non cavitary disease. However 
we did not find significant association between 
BMI and cavitary disease on CXR in our study.
Studies have shown that the bacterial burden 
increases with the radiographic severity of the 
disease irrespective of the presence or absence 
of cavitation [21]. Ralph et al. [12], in their study 
involving sputum smear positive PTB patients in 
Indonesia developed and validated the Timika 
CXR score. The score is a simple numerical sco-
re to grade the radiographic severity of disease 
extent and is found to be a predictor of 2-month 
sputum conversion status. At a cut-off level of 71, 
the score could predict a positive sputum smear 
at 2 months with a sensitivity of 80% and a speci-
ficity of 67.7% [12]. A recent study done in South 
Africa further validated the Timika CXR score 
and found a high inter-reader agreement or relia-
bility [29]. The median Timika CXR score of our 
study population was 59.5%. Higher CXR scores 
are significantly associated with higher sputum 
smear grade at diagnosis [12]. However Olaru et 
al. [30] in their study failed to demonstrate cor-
relation between CXR score with baseline smear 
grade. In our study we found that higher CXR 
score (≥ 71) was significantly associated with the 
baseline sputum smear grade as compared to lo-
wer CXR score (< 71). 62.2% of patients with CXR 
≥ 71 had 3+ sputum smear grade as compared to 
32.4% patients with lower CXR score (p < 0.04).
Ralph et al. [12]showed that the CXR scores 
were inversely related to BMI, FEV1, Hb% and 6 
min walk distance and directly related to SGRQ 
total score indicating the quality of life. Kriel 
et al. [29] also found that the mean CXR score 
for participants with baseline BMI < 18.5 kg/m2 
was significantly higher than those with higher 
BMI values [29]. We in our study also found that 
a higher CXR score was significantly associated 
with higher duration of symptoms, lower BMI and 
higher clinical scores (KPS, Bandim TB score and 
TB score II) at baseline (p < 0.001). 
The ESR is shown to be positively correlated 
with the radiological extent of disease on CXR [31]. 
We also found a significant association between 
CXR score and baseline ESR in our study popu-
lation (p < 0.04). Ralph et al. [12] concluded that 
the CXR score was significantly associated with 
a broader range of baseline severity measures than 
the presence of cavitation alone. Our study also 
shows that the Timika CXR score shows signifi-
cant correlation with various baseline clinical and 
microbiological parameters as compared to the 
presence of cavity alone. The Timika score is a re-
cently developed and validated chest x-ray score. 
We further tried to evaluate the score and its corre-
lation with multiple clinical outcomes and sputum 
bacterial load in assessing the severity of disease 
extent. And our study could show that the score 
correlates with a broader spectrum of disease se-
verity parameters as compared to cavitation alone.
Limitations
Our study is limited by the relatively small 
sample size, exclusion of HIV/AIDS patients in 
whom the CXR manifestations may be subtle and 
varied. Small cavitary lesions may be missed while 
interpreting the disease extent on CXR rather than 
CT. However CT is not feasible in all clinical settings.
Conclusion
Cavitary disease on CXR is associated with 
a higher mycobacterial load at baseline. Timika 
CXR score is a simple, standard scoring system 
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which can be used by a chest physician in a clini-
cal setting. The CXR score significantly correlates 
with a broad range of clinical and microbiological 
measures of disease severity in PTB patients. 
Thus, it has a role in risk stratification especially 
in patients not producing sputum or sputum ne-
gative PTB at diagnosis. Its role in comparing the 
extent of disease severity between two patients or 
time points and in predicting treatment response 
needs further validation. 
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